Allergan rose $1.70 or 1.8 percent, to $98.20. Baxter International Inc. rose$. 69 or 1.0 percent, to $67.39. Boston Scientific Corp. rose$. 51 or 4.5 percent, to $11.85.» Read More
WASHINGTON, June 28- Medical device maker Boston Scientific Corp said on Friday it would buy the electrophysiology business of C.R. Bard Inc for $275 million in cash, expanding its roster of products that help treat patients with an abnormal heartbeat.
CHICAGO, June 22- Type 1 diabetics, who run the risk of dangerously low blood sugar, may be a step closer to getting help from a crude artificial pancreas device that can read blood sugar levels and automatically turn off the flow of insulin after a clinical trial showed the device is safe.
NEW YORK, June 21- A unit of Endo Pharmaceuticals Inc said it has agreed to pay $54.5 million to settle some of the thousands of lawsuits in North America that it is facing over injury claims stemming from the use of transvaginal surgical mesh products.
Jim Cramer believes this company is about to create immense value with the stroke of a pen.
June 13- The U.S. Food and Drug Administration on Thursday urged medical device makers and medical facilities to upgrade security protections to protect against potential cyber threats that could compromise the devices or patient privacy.
The FDA issued an advisory that manufacturers, hospitals and patients need to protect themselves better from the introduction of malware in medical equipment and unauthorized access to settings that control devices.
When architect Michael Graves realized he would spend the rest of his life in a wheelchair, he set out to improve medical design. This week Stryker unveils his wheelchair.
Bristol-Myers Squibb and Merck stocks climbed higher Monday as analysts said billions stood to be made from treatment breakthroughs.
Americans accustomed to immediate access to the newest technology may be shocked to find that is not the case when it comes to devices that treat ailing hearts.
Cramer’s convinced the best way to for this health care company to maximize shareholder value is to break up.
The rise of "superbugs," and pressure from the government and insurers, is driving hospitals to try all sorts of new approaches to stop their spread.
Most robotic surgery takes place without a hitch, but a growing number of complaints and lawsuits allege complications and even deaths from Intuitive Surgical's da Vinci device.
If the critics of robotic surgery are right—that safety is an issue—how is that it was performed on 450,000 people last year? The answer may lie in one word: Marketing.
The number of complications from robot-assisted surgery using Intuitive Surgical's da Vinci robot are underreported, allege critics of the procedure, fanning the controversy around the company's pioneering product.
Intuitive Surgical's da Vinci robot was once hailed as a revolution in the operating room, but as more reports of complications have come to light, the da Vinci debate is heating up.
In recent years, as the surgical robot's popularity has grown, so have questions and concerns about its safety, training and the aggressiveness of its marketing.
A sharp and surprisingly persistent slowdown in the growth of health care costs is helping to narrow the federal deficit, leaving budget experts trying to figure out whether the trend will last.
An internal analysis conducted by Johnson & Johnson in 2011 estimated that the all-metal device would fail within five years in nearly 40 percent of patients who received it, newly disclosed court records show.
DaVita could be a beneficiary among health care stocks from changes in the U.S. health care market, an analyst said Wednesday.
It was a complicated case, in part because the reform legislation itself was seriously flawed. The law’s drafters could have proposed a simpler and more efficient system, the New York Times reports.